Dr. James McKim founded IONTOX in 2014 after spending over 20 years leading and advising research efforts as an assistant Professor at the University of Colorado School of Medicine, Team Leader for Biochemical Toxicology at Dow Corning, and a Science Fellow within Pharmacia (now Pfizer). Dr. McKim’s key areas of research have focused on understanding how chemicals effect key pathways controlling tissue health. Dr. McKim Co-Founded CeeTox, Inc. in 2003 a biotech company focused on in vitro strategies for predicting in vivo toxicity. He holds a Doctorate of Philosophy (Ph.D.) in Biochemical and Molecular Toxicology from Oregon State University, is the primary inventor on four patents, has numerous peer reviewed manuscripts, book chapters, and review articles, and has been a Diplomat of the American Board of Toxicology since 1995.
As a testament to Dr. McKim’s global impact on in vitro toxicology, in early 2015 he successfully launched a quarterly publication — “Applied In Vitro Toxicology” with Mary Ann Libebert, Inc., publishers. This new journal is international in its scope and reader base. As Editor-in-Chief, Dr. McKim was able to attract the renowned scientist Alan Goldberg, Ph.D., from Johns Hopkins University, as his Consulting Editor. In addition, he has put together an editorial board that includes leading scientists from global firms and institutions such as ScitoVation, Unilever, Dow Chemical, L’Oreal, and Pfizer.
Dr. Jamin A. Willoughby, Sr. received his Bachelors of Science (B.S.) in Biology from Indiana University – South Bend in 2002 and then went on to receive his Doctorate of Philosophy (Ph.D.) in Molecular and Cell Biology from the University of California, Berkeley in 2007. His dissertation focused on the molecular mechanisms of naturally occurring anti-cancer compounds in reproductive cancers (breast and prostate). Jamin has 9 years of in vitro toxicology experience, both as a Senior Research and Development (R&D) Scientist and as a Study Director, with CeeTox and Cyprotex. He is a member of the Society of Toxicology and has published numerous peer reviewed manuscripts. Jamin has substantial experience in assay development, in particular with three-dimensional tissue models, as well as expertise in many areas including dermal and ocular toxicity, genotoxicity and endocrine disruption. In 2017 Dr. Willoughby joined IONTOX as the Vice President of Toxicology.
Maryam Famourzadeh is the Managing Director of Double Helix M&A advisory firm based in San Diego. Prior to Double Helix M&A LLC, Maryam served as the M&A Advisor to Nuesoft Technologies, an EMR and EHR software company located in Atlanta, GA. Previously, she has served as the VP of Business Development at SalextBio, a life sciences strategy and business development advisory firm. Maryam was also the Team Leader and Senior Director of Pharmaceutical Sales at CeeTox Inc. where she structured the sales team and negotiated many sales, collaborations and alliances. She is the founder of Megagenex Biosciences and is the Founder of IALSN, a nonprofit life science company, where she served as the CEO from 2006-2015. She has also worked as senior research associates for University of California San Diego (UCSD) & Avanir Pharmaceuticals. Maryam attended UCSD and holds a BSc in Biochemistry and Cell Biology and has a Masters in Business Administration. In 2017 Maryam Famourzadeh joined IONTOX as the Vice President of Business Development and Marketing.
Nick Hibbard received his Bachelors of Science (B.S.) from Bowling Green State University in 2009 and then went on to receive a Masters of Science (MSc.) from the University of Liverpool in 2012 where he wrote his dissertation, “Accuracy and precision of liver based in vitro models relating to pre-clinical drug screening.’’ Nick has over seven years of experience within the field of toxicology working for leading research and toxicology based service organizations including CeeTox, Cyprotex, and Biogen. While at Biogen, Nick worked within the assay development group contributing to the development of assay’s in multiple therapeutic areas including sickle cell anemia, ALS, Cystic fibrosis, multiple sclerosis, and Alzheimer disease.
In 2016 IONTOX hired Nick Hibbard as the company’s Director of Laboratory Operations for their Kalamazoo based laboratories. Nick currently oversees the laboratory staff, design, execution, and review of experimental procedures along with all items relating to IONTOX laboratory services.
Bonnie Corpus received her B.S. in Biochemistry and Molecular Biology with a focus in Microbiology Biology from Michigan State University. She worked as a research assistant at Michigan State University and was the lab manager in a viral evolution lab at the University of Toledo. Past publications focused on viral fitness and adaptability as related to changes in genomic sequence. Her primary interest is in molecular toxicology. Bonnie joined IonTox in 2016 as a Research Scientist.